Reports have shown that GSK-3β upregulation in HCC predicts poor patient prognosis and that GSK-3β inhibition with short-hairpin RNA (shRNA) or specific inhibitors can decrease mTORC1 activity, glycolysis, and HCC growth in vivo [44]. The gene discussed is GSK3B; the disease is hepatocellular carcinoma.